Atossa Therapeutics taps seasoned life sciences executive from its board to be CFOProactive Investors • 06/01/23
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial OfficerGlobeNewsWire • 06/01/23
Atossa Therapeutics breast cancer drug trial milestones and CAR-T M&A likely catalysts, analysts sayProactive Investors • 05/24/23
Atossa Therapeutics' 1Q results show ongoing breast cancer drug studies and robust cash on handProactive Investors • 05/15/23
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/23
Atossa Therapeutics CEO Steven Quay weighs in on US agency's revised mammogram guidelinesProactive Investors • 05/11/23
Physician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and PracticesPRNewsWire • 05/11/23
Atossa Therapeutics to present insights from ongoing EVANGELINE clinical trial at ASCO Annual MeetingProactive Investors • 05/09/23
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 05/09/23
Atossa Therapeutics to Participate in Tribe Public's Webinar Event “Redefining Breast Cancer Prevention and Treatment”GlobeNewsWire • 04/27/23
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/22/23
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical TrialPRNewsWire • 03/21/23
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical TrialGlobeNewsWire • 03/21/23
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast CancerGlobeNewsWire • 02/23/23
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for EndoxifenGlobeNewsWire • 02/13/23
Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public RelationsGlobeNewsWire • 12/07/22
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/22
Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T StrategyGlobeNewsWire • 11/01/22